Publications by authors named "Sameer R Ghate"

Claim this Profile
P
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer.
Niven Mehra, Emmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, Ray McDermott, Sameer R Ghate

Eur Urol Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.
Nobuaki Matsubara, Daniel Petrylak, Raffaele Ratta, Ernesto Korbenfeld, Rustem Gafanov, Sameer R Ghate

Eur Urol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe.
Elena Castro, Chinelo Orji, Amanda Ribbands, Jake Butcher, Maria Walley, Sameer R Ghate

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer.
Jun Gong, Jessica L Janes, Claire Trustram Eve, Shannon Stock, Justin Waller, Sameer R Ghate

Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan.
Andrea Leith, Jeri Kim, Amanda Ribbands, Emily Clayton, Lingfeng Yang, Sameer R Ghate

Adv Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.
Andrea Leith, Amanda Ribbands, Jeri Kim, Matthew Last, Sophie Barlow, Sameer R Ghate

Future Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.
Andrea Leith, Amanda Ribbands, Jeri Kim, Emily Clayton, Liane Gillespie-Akar, Sameer R Ghate

BMC Urol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
Neal D Shore, Raluca Ionescu-Ittu, François Laliberté, Lingfeng Yang, Dominique Lejeune, Sameer R Ghate

Clin Genitourin Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Rachel Evans, Neil Hawkins, Pascale Dequen-O'Byrne, Charles McCrea, Dominic Muston, Sameer R Ghate

Target Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
Neal Shore, Raluca Ionescu-Ittu, Lingfeng Yang, François Laliberté, Malena Mahendran, Sameer R Ghate

Future Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors.
Neal D Shore, François Laliberté, Raluca Ionescu-Ittu, Lingfeng Yang, Malena Mahendran, Sameer R Ghate

Adv Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Margaret E Gerbasi, Daniel Stellato, Sameer R Ghate, Briana Ndife, Aaron Moynahan

J Med Econ· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
Daniel Stellato, Margaret E Gerbasi, Briana Ndife, Sameer R Ghate, Aaron Moynahan

J Manag Care Spec Pharm· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
Jason J Luke, Sameer R Ghate, Jonathan Kish, Choo Hyung Lee, Lindsay McAllister

Future Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy.
Sameer R Ghate, Raluca Ionescu-Ittu, Rebecca Burne, Briana Ndife, François Laliberté

Curr Med Res Opin· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.
Ahmad Tarhini, Sameer R Ghate, Raluca Ionescu-Ittu, Ameur M Manceur, Briana Ndife

Melanoma Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly.
Sameer R Ghate, Zhiyi Li, Jackson Tang, Antonio Reis Nakasato

Am Health Drug Benefits· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Nicholas J Vogelzang, Sumanta K Pal, Sameer R Ghate, Nanxin Li, Elyse Swallow

J Manag Care Spec Pharm· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Nicholas J Vogelzang, Sumanta K Pal, Sameer R Ghate, Elyse Swallow, Nanxin Li

Adv Ther· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the US.
Victor M Villalobos, Stacey DaCosta Byfield, Sameer R Ghate, Oluwakayode Adejoro

Clin Sarcoma Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
Sumanta K Pal, Sameer R Ghate, Nanxin Li, Elyse Swallow, Miranda Peeples

Clin Genitourin Cancer· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
Shannon L Reynolds, Sameer R Ghate, Richard Sheer, Pranav K Gandhi, Chad Moretz

Health Qual Life Outcomes· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a Qualitative Study to Develop a Patient Reported Outcome Measure for Patients with 4 Subtypes of Soft Tissue Sarcoma.
Anne M Skalicky, Sameer R Ghate, Jose Ricardo Perez, Anne M Rentz

Sarcoma· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.
Sumanta K Pal, James E Signorovitch, Nanxin Li, Miriam L Zichlin, Zhimei Liu, Sameer R Ghate

Int J Urol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation.
Joseph Biskupiak, Sameer R Ghate, Tianze Jiao, Diana Brixner

J Manag Care Pharm· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis